CD19+ B-Cell Lymphocyte Count (Absolute)
This test measures the number of CD19+ cells in your blood, which are a type of white blood cell involved in immune function. CD19 is a protein found on the surface of B-cells, a key part of the immune system.
["CD19+ cells help fight infections and contribute to immune responses; this test helps assess immune health or monitor conditions affecting B-cells."]
Key facts at a glance
- LOINC
- 20593-0
- Short code
- CD19
- Synonyms
- CD19 Cells NFr Spec
- Category
- chemistry
- Sample
- serum
- Container
- EDTA (lavender-top) or heparinized (green-top) tube for whole blood; sterile container for tissue/bone marrow specimens
- Units
- N/A
- Ref low
- 5
- Ref high
- 15
- Fasting
- false
- Population
- adult
- Sex
- all
- Age range
- 0–120 years
- Method
- Flow cytometry using fluorescently-labeled monoclonal antibodies against CD19 surface marker, typically performed on whole blood or bone marrow specimens
- CPT
- 86355
- SNOMED
- 116981002
- Specimen volume
- 3-5 mL of whole blood; minimum 1 mL for pediatric or tissue specimens
- Stability
- Specimen should be processed within 24-48 hours of collection. Store at room temperature (18-22°C). Do not refrigerate. Specimen stability may vary by laboratory protocol.
- Hemolysis max
- 500
- Lipemia max
- 1000
- Icterus max
- 500
- TAT
- 24–72 hours
- Order
- routine
Why This Test Might Be Ordered
Your healthcare provider may order this test to evaluate immune function, diagnose or monitor conditions like chronic lymphocytic leukemia (CLL), lymphoma, or other B-cell-related disorders. It may also be used before or after treatments that affect the immune system, such as chemotherapy or bone marrow transplants.
What to Expect Before the Test
No special preparation is needed. You may have a simple blood draw, usually done in a clinic or lab. The process is quick and typically painless. If you’re on blood-thinning medication, let your provider know before the test.
What the Test Results Mean
Results show the absolute count of CD19+ cells per microliter of blood. Abnormal counts (either high or low) may indicate immune system issues or diseases affecting B-cells. Your provider will interpret results in the context of your overall health and medical history.
Common Conditions Monitored or Diagnosed
This test is often used to diagnose or monitor conditions such as B-cell lymphoma, chronic lymphocytic leukemia, or other immune-related disorders. It can also help track the effectiveness of treatments targeting B-cells.
Reference range
Reference ranges vary by laboratory and specimen type. CD19+ B-lymphocytes typically represent 5-15% of total lymphocytes in peripheral blood. Absolute counts vary by age.N/A
No special patient preparation required. Recent immunotherapy (e.g., rituximab, CAR-T therapy), chemotherapy, or immunosuppressive medications may significantly affect CD19+ cell counts. Inform the laboratory of relevant clinical history.
Clinical interpretation
How abnormal results are interpreted and what conditions they suggest.
Clinical Significance: CD19+ Cells Play a Critical Role in Immune Defense
Short name
CD19+ Cells
Frequently asked questions
How is the test performed?
What if my test results are abnormal?
Can I eat or drink before this test?
Sources
- 1
- 2Lab Tests OnlineSource
- 3
Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 16, 2026. · Read our editorial policy